Healthcare Services

Cancer cachexia market forecast to reach $3.35B by 2030 at 5.1% CAGR

April 20, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Cancer Cachexia Market During 2026–2030?

The cancer cachexia market has shown significant growth over recent years. It is anticipated to increase from $2.6 billion in 2025 to $2.75 billion in 2026, advancing at a compound annual growth rate (CAGR) of 5.8%. The expansion observed in prior periods can be attributed to several factors, including a higher occurrence of late-stage cancer diagnoses, enhanced clinical understanding regarding cachexia management, the expanding distribution channels through hospital pharmacies, the early adoption of anabolic agents, and the broader provision of supportive oncology care.

The market for cancer cachexia is projected to experience substantial expansion over the upcoming years, with an anticipation to reach $3.35 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.1%. This projected growth is driven by several factors, including a greater need for individualized cachexia therapies, an uptick in clinical investigations into new underlying mechanisms, the broadening of outpatient oncology support, wider adoption of digital monitoring for patients, and a heightened emphasis on improving quality-of-life results. Key trends anticipated during this period encompass the increased application of multi-drug treatment plans, a heightened emphasis on therapies aimed at preserving muscle mass, the wider uptake of nutritional support approaches, the spread of anti-inflammatory interventions for cachexia, and improved surveillance of cachexia’s advancement.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Which Key Drivers Are Affecting The Cancer Cachexia Market Development?

The expanding occurrence of cancer is projected to fuel the expansion of the cancer cachexia market in the coming years. Cancer is characterized as a medical state where atypical cells multiply without control within the body, leading to tumor formation and disruption of normal physiological functions. The rise in cancer incidents can be linked to several elements, such as evolving lifestyles, environmental influences, an aging demographic, inherited predispositions, enhanced diagnostic techniques enabling earlier identification, and heightened public awareness, encouraging more individuals to seek medical evaluation. Breakthroughs in medical technology and a deeper comprehension of cancer and its associated complications are contributing to a higher frequency of cancer cachexia diagnoses and reported cases. Medical practitioners are enhancing their capability to pinpoint cachexia symptoms, thereby allowing for earlier interventions and the initiation of treatment. To illustrate, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that an approximate 165,000 Australians received a new cancer diagnosis in 2023, translating to more than 450 cases daily, with men accounting for about 55% of these diagnoses. Consequently, the rising prevalence of cancer is propelling the growth of the cancer cachexia market.

How Is The Cancer Cachexia Market Segmented Across Different Segment Categories?

The cancer cachexia market covered in this report is segmented –

1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate, Medroxyprogesterone Acetate

2) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids, Progestogens + Anabolic Agents, Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents, Appetite Stimulants, Anti-inflammatory Drugs

What Trends Are Transforming The Cancer Cachexia Market?

Leading companies within the cancer cachexia market are actively creating innovative medications, including monoclonal antibodies for cachexia, with the aim of developing a targeted treatment for the condition. These treatments seek to improve patients’ body weight, muscle mass, and overall quality of life. A monoclonal antibody designed for cachexia functions by targeting and inhibiting the specific factors that lead to muscle and weight loss. For example, in September 2024, Pfizer Inc., a US-based pharmaceutical company, publicly shared the positive results from its Phase 2 study of Ponsegromab. This particular monoclonal antibody targets GDF-15 in patients afflicted with cancer cachexia. The study revealed a significant increase in body weight, alongside enhancements in muscle mass, appetite, and physical activity, with the 400 mg dose yielding the most robust outcomes. Encouraged by these promising discoveries, Pfizer intends to initiate registration-enabling studies in 2025 to further assess Ponsegromab’s potential as a treatment for cancer cachexia.

Which Organizations Play A Role In The Cancer Cachexia Market Landscape?

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

Get The Full Cancer Cachexia Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Which Region Represents The Largest Share Of The Cancer Cachexia Market?

North America was the largest region in the cancer cachexia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cancer Cachexia Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Browse Through More Reports Similar to the Global Cancer Cachexia Market 2026, By The Business Research Company

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Chemotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795